Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 25, Issue 4, pp 295–298 | Cite as

Phenotypic variations dictate the intracellular compartmentalization of doxorubicin in normal human bone marrow cells

  • Esther Aghaï
  • Zoltán A. Tökés
Article

Summary

In vitro accumulation of doxorubicin in intracellular compartments of normal bone marrow cells was studied with the use of fluorescent microscopy. Both the cytoplasmic and nuclear compartments had distinguishable drug accessibility in the diverse hemopoietic series and in different stages of maturation of each lineage. Nuclei appeared to be more sheltered in the myelogranulogytic series and macrophages appeared to be the least Nuclei of activated phagocytic cells of the myelogranulocytic series and macrophages appeared to be the least accessible to doxorubicin uptake. These observations establish that phenotypic variations dictate the patterns of anthracyclines' subcellular compartmentalization. They also suggest that the molecular mechanism contributing to the intracellular trafficking of doxorubicin deserves more substantial investigation that may contribute to our understanding of drug resistance and sensitity.

Keywords

Doxorubicin Phenotypic Variation Bone Marrow Cell Anthracyclines Normal Bone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Batist G, Tulpule A, Sinha BK, Katki AG, Myer CA, Covan CH (1986) Overexpression of a novel anionic glutathione transferase in multiple drug resistance of human breast cancer cells. J Biol Chem 261:15544–15549Google Scholar
  2. 2.
    Beck WT (1987) The cell biology of multiple drug resistance. Biochem Pharmacol 36 (18):2879–2887Google Scholar
  3. 3.
    Burke TG, Tritton TR (1985) Location and dynamics of anthracyclines bound to unilamellar phosphatidylcholine vesicles. Biochemistry 24(21):5972–5980Google Scholar
  4. 4.
    Crooke ST (1981) The anthracyclines. In: Cancer and chemotherapy, vol III. Academic, New York: pp 111–132Google Scholar
  5. 5.
    Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT (1988) Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27:8861–8869Google Scholar
  6. 6.
    Drilca K, Franco RJ (1988) Inhibitors of DNA topoisomerases. Biochemistry 27:2253–2259Google Scholar
  7. 7.
    Goldman R, Facchinetti T, Raz A, Bach D, Shinitzky M (1979) Differential interaction of daunomycin, Adriamycin and their derivatives with macrophages, human erythrocytes and phospholipid bilayers (Meeting Abstract). Isr J Med Sci 15(1): 70Google Scholar
  8. 8.
    Hamada H, Tsuruo T (1988) Characterization of ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug-resistant K562/ADR cells. Cancer Res 48(17):4926–4932Google Scholar
  9. 9.
    Kleinerman ES, Zwelling LA, Schwartz R, Muchore AV (1982) Effect ofl-phenyl alanine mustard, Adriamycin, actinomycin D, and 4′-(9-acridinylamino)methansulfon-m-anisidide on naturally occurring human spontaneous monocytemediated cytotoxicity. Cancer Res 42:1692–1695Google Scholar
  10. 10.
    Krishan A, Sridhar KS, Davila E, Vogel C, Sternheim W (1987) Patterns of anthracycline retention, modulation in human tumor cells. Cytometry 8:306–314Google Scholar
  11. 11.
    Mikkelsen RB, Lin PS, Wallach DFH (1977) Interactions of Adriamycin with human red blood cells: a biochemical and morphological study. J Mol Med 2:33–40Google Scholar
  12. 12.
    Nooter K, Eng G van den, Sonneveld P (1983) Quantitative flow cytometric determination of anthracycline content of rat bone marrow cells. Cancer Res 43:5126–5130Google Scholar
  13. 13.
    Ross KL, Stolinsky DC, Tökés ZA (1986) Accumulation of Adriamycin into the cytoplasmic compartment by resistant L1210 cells. Proc Am Assoc Cancer Res 27:271Google Scholar
  14. 14.
    Tritton TR, Lane P (1986) Temperature dependence of Adriamycin uptake and cytotoxicity. Proc Am Assoc Cancer Res 27:246Google Scholar
  15. 15.
    Vaudaux P, Kiefer B, Forni M, Joris I, Majno G, Waldvogel A (1984) Adriamycin impairs phagocytic function and induces morphologic alterations in human neutrophils. Cancer 54:400–410Google Scholar
  16. 16.
    Willingham MC, Cornwell MM, Cardarelli CO, Gottesman MM, Pastan I (1986) Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and-sensitive KB cells: effect of verapamil and other drugs. Cancer Res 46:5941–5946Google Scholar
  17. 17.
    Willingham MC, Richer ND, Cornwell MM, Tsuruo T, Hamada H, Gottesman MM, Pastan I (1987) Immunochemical localization of P170 at the plasma membrane of multidrug-resistant human cells. J Histochem Cytochem 35(12): 1451–1456Google Scholar
  18. 18.
    Yee G, Carey M, Tritton TR (1984) Photoaffinity labelling of the sarcoma 180 cell surface by daunomycin. Cancer Res 44(5):1898–1903Google Scholar
  19. 19.
    Young RC, Ozols RF, Myers CE (1985) The anthracycline antineoplastic drugs. New Engl J Med 305:139–153Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • Esther Aghaï
    • 1
    • 2
  • Zoltán A. Tökés
    • 1
    • 2
  1. 1.Department of Hematology/OncologyChildren's Hospital of Los AngelesLos AngelesUSA
  2. 2.Department of Biochemistry, Comprehensive Cancer Center, School of MedicineUniversity of Southern CaliforniaLos AngelesUSA

Personalised recommendations